GlassScriptPhysician profile
Taylor Price
NPI 1891480588
$1,864.20
in general payments reported to CMS, 2019-2025
19 companies · $689 in 2025
The $689 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $319 · 2024: $856 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $402.93 | 2024-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Indivior INC. | $216.66 | 2023-2025 | Sublocade |
| Edwards Lifesciences Corporation | $186.42 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $129.98 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $128.81 | 2024 | Kyphon Express II Kyphopak Tray |
| Braeburn INC. | $122.69 | 2024-2025 | Brixadi |
| Glaxosmithkline, LLC. | $117.16 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $88.38 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $82.56 | 2023-2025 | |
| Novo Nordisk INC | $69.87 | 2024-2025 | Wegovy |
| Abbott Laboratories | $68.26 | 2024-2025 | Proclaim, Freestyle Libre 3 |
| Amgen INC. | $66.25 | 2024 | Repatha, Otezla |
| Abbvie INC. | $47.63 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.98 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $25.28 | 2025 | Recorlev |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Digestive Care, INC. | $23.43 | 2025 | Pertzye |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.18 | 2024 | |
| Inspire Medical Systems, INC. | $17.29 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $13.44 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.